Similarly, TβRI-KI LY2157299 (Galunisertib) can block the conduction of the TGF-β pathway and inhibit the development of drug-resistant CSCs and tumor recurrence induced by paclitaxel (160). Here, TGFB1 is linked to neoplasm.